Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Sci Writers / shutterstock.com

FDA’s Arthritis Advisory Committee Narrowly Endorses Avacopan Approval

Ruth Jessen Hickman, MD  |  August 11, 2021

On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…

Filed under:ConditionsDrug UpdatesVasculitis Tagged with:ANCA-Associated VasculitisavacopanGlucocorticoids

Colchicine: An Ancient Drug with Modern Uses

Ibrahem Salloum, MD, & Deepan S. Dalal, MD, MPH  |  August 11, 2021

Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:anti-inflammatoryColchicinedrug treatmentGoutinflammation

Therapeutic Drug Monitoring May Offer Little Benefit to Patient Remission Rates During Infliximab Induction Therapy

Lara C. Pullen, PhD  |  August 9, 2021

Although rheumatologists prescribe tumor necrosis factor inhibitors (TNFi’s) to treat several rheumatic diseases, they recognize immunogenicity influences the efficacy and safety of TNFi’s. Example: The formation of anti-drug antibodies can affect infusion reactions and cause low-serum drug levels and therapeutic failure. The induction phase is a period of high incidence of immunogenicity, and observational data…

Filed under:Drug Updates Tagged with:infliximabtherapeutic drug monitoringTNF inhibitorTNFitumor necrosis factor inhibitor (TNFi)

Efficacy of Tocilizumab Monotherapy After Ultra-Short Glucocorticoid Administration in GCA

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2021

In a small study, patients with GCA maintained remission after receiving three days of treatment with methylprednisolone followed by tocilizumab.

Filed under:Drug UpdatesMeeting ReportsVasculitis Tagged with:EULARGCAgiant cell arteritis (GCA)GlucocorticoidsmonotherapyRemissiontocilizumab

Janus Kinase Inhibitors Promising for Difficult-to-Treat RA

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2021

In a study, Janus kinase inhibitors proved effective for patients with difficult-to-treat rheumatoid arthritis (RA).

Filed under:Drug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:baricitinibEULARJAK inhibitorjakinibJanus Kinase InhibitorsRheumatoid Arthritis (RA)Tofacitinib

Treatment Factors to Consider in Patients with JIA

Jason Liebowitz, MD, FACR  |  July 18, 2021

Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.

Filed under:ConditionsMeeting Reports Tagged with:JIAjuvenile idiopathic arthritis (JIA)Pediatric RheumatologyPediatric Rheumatology SymposiumPRSYMTreatment

The Many Facets of JIA: Insights from Bench to Bedside for the Clinical Care of Patients with JIA

Jason Liebowitz, MD, FACR  |  July 18, 2021

Experts provide insights into spondyloarthropathy, temporomandibular joint involvement and imaging for pediatric patients with JIA.

Filed under:ConditionsMeeting ReportsPediatric Conditions Tagged with:imagingpatient carePediatricPediatric RheumatologyPediatric Rheumatology SymposiumPRSYMspondyloarthropathytemporomandibular joint (TMJ)

More Equal Care: The Power of Diversity, Equity & Inclusion in Rheumatology

Jason Liebowitz, MD, FACR  |  July 17, 2021

Diversity, equity and inclusion have implications for pediatric patient care and the rheumatology workforce.

Filed under:Meeting ReportsProfessional Topics Tagged with:Diversityhealth disparitiesinclusionPediatric Rheumatology SymposiumPRSYMrace

Achieving Excellence in Pediatric Rheumatology Clinical Care

Jason Liebowitz, MD, FACR  |  July 17, 2021

PRSYM—At its heart, the practice of medicine in all forms is specifically centered on delivering compassionate, thoughtful and evidence-based clinical care. In the world of pediatric rheumatology, a range of issues, such as chronic pain, reproductive health and transitioning to adult providers, are of utmost importance to patients and physicians alike. These topics were addressed…

Filed under:ConditionsMeeting ReportsPain SyndromesPediatric Conditions Tagged with:Chronic painpatient carePediatricPediatric RheumatologyPediatric Rheumatology SymposiumPRSYMreproductive healthtransition

Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA

Jason Liebowitz, MD, FACR  |  July 16, 2021

JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.

Filed under:ConditionsMeeting Reports Tagged with:eyesJIA-associated uveitisjuvenile idiopathic arthritis (JIA)lungsPediatric RheumatologyPediatric Rheumatology SymposiumPRSYMsJIAsJIA-associated lung disease

  • « Previous Page
  • 1
  • …
  • 65
  • 66
  • 67
  • 68
  • 69
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences